JUPW dropped major news this AM. Check it out:


Nasdaq Profile (JUPW) Drops Huge Trial Related News This Morning, Must Read Now

Yahoo Finance Reports Float Of Only 5.89Mn Shares

July 13th

Good Morning,

JUPW dropped major news this AM. Check it out:

Jupiter Wellness Announces initiation of Head-to-Head Trial Comparing JW-100 and Eucrisa(R) for the Treatment of Mild-to-Moderate Eczema

JUPITER, FL / ACCESSWIRE / July 13, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced a head-to-head trial comparing JW-100 lotion with Eucrisa crisaborole ointment 2% for the treatment of patients with mild to moderate eczema (Atopic Dermatitis). Eucrisa is an FDA-approved topical non-steroidal lotion containing crisaborole approved for the treatment of mild to moderate eczema. JW-100 is a novel non-steroidal topical lotion containing canna-bid-iol (cb) and Aspertame for the treatment of mild to moderate eczema.

The head-to-head clinical trial which will evaluate superiority between JW-100 and Eucrisa in adult patients with mild-to-moderate eczema will be performed in collaboration with Applied Biology who has developed the protocols and will co-ordinate the multi-center trial. The Phase III multi-center trial will be a double-blinded placebo controlled trial.

This head-to-head trial is built on the success of our previous clinical findings for JW-100. Jupiter Wellness previously reported in a double-blinded, placebo controlled clinical trial of 55 patients using JW-100 a novel topical formulation containing CB and Aspartame, was shown to significantly reduce ISGA scores in 50% of adult patients suffering from eczema after two weeks of use. The results were recently published pubmed.ncbi.nlm.nih.gov/34056830/.

"Jupiter Wellness is committed to providing rapid-and-consistent relief for eczema patients. In light of the highly encouraging results of JW-100's first clinical trial, head-to-head trials can provide robust evidence that helps advance our clinical program," said Dr. Glynn Wilson Chief Scientific Officer at Jupiter Wellness.

"The purpose of this trial is to confirm the efficacy of JW-100 in a larger patient population in direct comparison with an FDA-approved non-steroidal topical drug. Our goal is to commercialize both OTC and prescription versions of JW-100. Our recent licensing of Photocil provides a unique opportunity for combination therapies including am/pm eczema treatment regimines." stated Brian John, Jupiter Wellness' CEO.

Read the full article here.

Could this be the news to spark JUPW to a potential breakout?

Remember, this is a low float profile as Yahoo Finance reports a float of approximately 5.89Mn shares.

Plus, JUPW continues to trade above 3 key lines of potential technical support in its 5-Day Simple Moving Average (SMA), its 20-Day SMA, and its 50-Day SMA.

Take a moment now to read my initial report below and get JUPW on your radar this morning.


*Jupiter Wellness, Inc. (NASDAQ:JUPW)*

Jupiter Wellness, Inc. is a leading developer of canna-bid-iol ("CB") based medical therapeutics and wellness products. The Company's clinical pipeline of prescription CB-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer.

Jupiter generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun™ sunscreen and other wellness brands sold through its robust distribution platform.

Jupiter Wellness Company Game Plan

Here's a breakdown of how JUPW plans to become an industry leader:

  • CB-based topical therapeutics targeting multiple Bn-dollar treatment markets
  • Strategy to launch over-the-counter (OTC) version of products leading up to FDA-approved prescription therapeutics
  • Building a portfolio of proprietary, patent-pending skincare products including flagship CaniSun™ brand of sunscreens
  • Generating high-margin revenues through OTC and wellness product sales
  • In-creasing current cash flows through acquisition of new wellness brands and ecommerce distribution platforms
  • Management team with expertise and performance track record in pharma clinical trials and OTC wellness market


JUPW Trial Info For Future Potential Products


No. 1 Potential JUPW Catalyst - Low Float

According to Yahoo Finance, JUPW has a small float.

The website reports this profile to have 5.89Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, potential driver indicators can send shares heading vertical in the short-term.


No. 2 Potential JUPW Catalyst - History Of Short Term Breakouts

Check out JUPW's chart:


On multiple occasions, this low float profile has demonstrated the ability to break out in epic fashion.

Here's a handful of times over the past year to take note of:

  1. On 12/16/20, JUPW hit a low of $4.47 before surging to a high of $8.35 one day later. That $3.00+ move resulted in JUPW rocketing 86%.
  2. On 1/11/21, JUPW blazed $2.00+ from an open of $5.02 to a high of $7.63. That move resulted in a 51% run intraday.
  3. On 2/23/21, JUPW moved a $1.00+ from an open of $6.15 to a high of $7.70 for an overall intraday breakout of 25%.
  4. On 3/5/21, JUPW dropped to a low of $4.30 before shooting $2.00+ to a high of $6.66 on 3/11/21. That short term breakout resulted in a move of 54%.

Now, this is only a handful of instances. Just take a look at the chart above and you can see all the times this profile moved quickly in the short term.


No. 3 Potential JUPW Catalyst - Big Licensing News Friday

Jupiter Wellness Licenses Photocil(TM), a Novel Topical Treatment of Psoriasis, Vitiligo, Pruritis and Atopic Dermatitis

JUPITER, FL / ACCESSWIRE / July 9, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced they have entered into an exclusive agreement to license Photocil™, a novel patented topical cream that provides clinically-proven relief for Psoriasis, Vitiligo and Atopic Dermatitis.


"Licensing of Photocil™ allows Jupiter Wellness to offer additional treatments to patients suffering from skin ailments and AM/PM or combination therapy. We plan to register Photocil with the FDA and begin marketing the product immediately," stated Dr Glynn Wilson, Chief Scientific Officer of Jupiter Wellness.

Read the full article here.


No. 4 Potential JUPW Catalyst - Publishing Of Clinical Study Results

Results of Clinical Study Showing That JW 100 Significantly Reduces ISGA Score in Atopic Dermatitis (AD) Published

JUPITER, FL / ACCESSWIRE / June 22, 2021/Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced the publication of clinical study results to investigate the safety and efficacy of JW-100 its proprietary lotion formulation for the treatment of atopic dermatitis (eczema).


Dr Glynn Wilson, Chief Scientific Officer of Jupiter Wellness commented, "Peer-reviewed publication of data from controlled clinical trials conducted by leading clinicians is central to our overall strategy of developing novel medicinal products that have demonstrated safety and efficacy and ultimately receive regulatory approval."

Brian John, CEO of Jupiter Wellness added "We are excited by these initial results and the potential for JW-100 to provide a solution superior to existing prescription dr-ugs. The early clinical data shows JW-100's potential to disrupt the Bn-dollar market for the treatment of eczema."

Read the full article here.


No. 5 Potential JUPW Catalyst - Signing Of Potential Game-Changing LOI

Jupiter Wellness Enters into LOI to Acquire JustCB and its Affiliates

Article Highlights:

Brian John, CEO of Jupiter Wellness commented, "... We believe this acquisition will be highly accretive to Jupiter and its shareholders and puts us at the forefront of CB consumer related products on the market."


Nasdaq Profile (JUPW) Recap: Top Potential Catalysts

#1. Low Float

#2. History Of Short Term Breakout

#3. Big Licensing News Friday

#4. Publishing Of Clinical Study Results

#5. Signing Of Potential Game-Changing LOI


Coverage is officially initiated on JUPW. When you have time later, do this:


If there are any more updates today, I'll get them out to you quickly.


Kai Parker


Source 1

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading Stock Wire News email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 7/12/21 and ending on 7/13/21 to publicly disseminate information about (JUPW) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (JUPW).